Latest Drug development biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

Nuevo paso frente a las recaídas en cáncer

by Universidad Politécnica de Madrid

3 months ago
moléculas (Carboxy-PEDF, CTER-PEDF)

Investigadores de la UPM trabajan en el desarrollo de nuevos fármacos que permitan evitar la recaída y mejoren la respuesta de los pacientes al tratamiento con quimioterapia.

First MYC inhibitor to demonstrate safety and anti-tumor activity in a phase I first-in-human clinical trial

by VHIO

3 months ago
Omomyc (OMO-103), MYC

Results of the first-in-human phase I trial of OMO-103 demonstrate its safety and promising anti-tumor activity and shows how this MYC inhibitor can stabilize or even reduce disease burden in some hea...

El CSIC acoge un espectrómetro de resonancia magnética nuclear único en Europa

by CSIC - Centro Superior de Investigaciones Científicas

3 months ago
biomoléculas, Resonancia Magnética Nuclear (RMN), espectroscopia de RMN

El laboratorio Manuel Rico del IQF-CSIC, que analiza la estructura de las moléculas, se actualiza con un espectrómetro especialmente configurado para estudiar biomoléculas hasta ahora inabordables ...

I3PT, CONNECTA Therapeutics, CRG and IMIM receive 2,7 million from the Ministry of Science and Innovation to start Phase IIa of the drug CTH120 for fragile X syndrome

by Instituto de Investigación e Innovación Parc Taulí

2 months ago
Fragile X syndrome (FXS), CTH120

The Phase IIa study will evaluate the efficacy of CTH120 as an innovative therapy in adult patients with FXS, the most common form of inherited intellectual disability without a specific treatment

XNA-HUB, platform to boost therapeutic modified oligonucleotides

by Institute for Advanced Chemistry of Catalonia (IQAC-CSIC)

2 months ago
XNA, “Xeno Nucleic Acid”

The project to create the XNA-HUB platform receives a significant boost thanks to PERTE funding. The platform will design therapeutic molecules based on modified nucleic acids using supercomputing tec...

Nearly 3 million euros to initiate Phase IIa of CTH120 drug for Fragile X syndrome

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

2 months ago
CTH120, Fragile X syndrome

The Ministry of Science, Innovation and Universities and the European Union, through the Next Generation EU program will finance this new phase. It will evaluate the efficacy of CTH120 as an innovativ...

NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)

by Ysios Capital

2 months ago
intestinal failure-associated liver disease (IFALD), NorthSea Therapeutics B.V., Orziloben (NST-6179)

NorthSea Therapeutics B.V. today announced the dosing of the first patient in its Phase 2a clinical trial of Orziloben (NST-6179) in intestinal failure-associated liver disease (IFALD), an orphan live...

CIC bioGUNE presents the new Nuclear Magnetic Resonance (NMR) facilities

by CIC bioGUNE

2 months ago
1 GHz, Nuclear Magnetic Resonance (NMR)

With this latest acquisition of 1 GHz equipment, the CIC bioGUNE NMR facilities are now among the most advanced in southern Europe, highlighting the capacity of the research centre to lead research in...

ORYZON reports financial results and corporate update for quarter ended December 31, 2023

by Oryzon Genomics

2 months ago
Oryzon Genomics

yzon Genomics, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reported financial results for the fourth quar...

ARTHEx Biotech, backed by Columbus Venture Partners, receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

by ARTHEx Biotech

2 months ago
Myotonic Dystrophy Type 1 (DM1)., ATX-01, ArthemiRTM, MBNL proteins, ARTHEx Biotech, Columbus Venture Partners

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs backed by Columbus Venture Partners, has announced that the ...

Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data Monitoring Committee to advance to the next stage of CLINGLIO, the phase 2b/3 Clinical Trial of LAM561 in combination with RT and TMZ for adults with newly diagnosed glioblastoma.

by Laminar Pharma

2 months ago
Laminar Pharmaceuticals, LAM561, glioblastoma (GBM), CLINGLIO trial

The independent data monitoring committee (IDMC) has recommended continuation of CLINGLIO without modification after its assessment of LAM561 interim efficacy in newly diagnosed Glioblastoma. This fol...

PBF-999, the first in class treatment in development for the Prader-Willi Syndrome has received “Orphan Drug Designation” by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA)

by Palobiofarma

2 months ago
Prader-Willi Syndrome, PBF-99

The Orphan Drug Designation indicates the acknowledgement by the Regulatory Authorities of USA and the EU that PBF-999 have the potential to address the specific needs of individuals suffering from Pr...